Portrait of Jack S. Resneck
ucsf logo

Jack S. Resneck, MD

DermatologyChair, UCSF Department of Dermatology
Dermatology Mount Zion
415-353-7800
Portrait of Jack S. Resneck
Portrait of Jack S. Resneck
ucsf logo

Jack S. Resneck, MD

DermatologyChair, UCSF Department of Dermatology
Dermatology Mount Zion
415-353-7800

On this page

About me

Dr. Jack S. Resneck Jr. is a dermatologist who cares for patients with a wide range of skin diseases.

In research, areas of Resneck's studies include patient access to care, health care delivery and affordability, digital medicine and public health. His work has been published in prominent journals and attracted national media attention.

Raised in Louisiana, Resneck received his bachelor's degree in public policy from Brown University. He earned his medical degree from UCSF, where he also completed a residency in dermatology and a fellowship in health policy.

Resneck serves on the editorial board of the Journal of the American Academy of Dermatology. He chaired the World Medical Association's global 30-month process to revise and modernize the Declaration of Helsinki, the seminal document defining the ethical principles and protections governing medical research with human participants. He chaired the board of trustees of the American Medical Association (AMA) from 2018 to 2019 and served as AMA president from 2022 to 2023. He also has served on the board of the National Quality Forum and as president of the California Society of Dermatology and Dermatologic Surgery.

Resneck is a passionate advocate for both doctors and patients. He frequently speaks as a champion of well-tested health care innovation and a more equitable health care system. Whether testifying before Congress about addressing health care dysfunction and burdens, advocating for easier patient access or leading the dermatology department, he seeks to build stronger, healthier communities by improving the lives of patients and the working environment for doctors in the United States.

Resneck is also committed to educating future doctors. He chairs the UCSF Department of Dermatology and is the UCSF Bruce U. Wintroub Endowed Professor of Dermatology. He serves as affiliated faculty at the UCSF Philip R. Lee Institute for Health Policy Studies.

Education & training

Board certification

  • Dermatology, American Board of Dermatology

Residency

  • Dermatology, UCSF Medical Center - OMAG

Internship

  • Internal Medicine, UCSF Medical Center - OMAG

Degree

  • MD, University of CA at San Francisco

Locations

    Reviews

    Average rating

    5
    5 out of 5 Stars
    174 ratings
    About provider reviews

    Showing 1-6 of 35 reviews

    Sort by
    • 5 out of 5 Stars
      December 17, 2025

      Dr. Resneck is a wonderful doctor and human being. He is compassionate, really listens, does not appear to be in a hurry, gives great advice, has a good sense of humor, and is everything anyone might want in a doctor.

    • 5 out of 5 Stars
      December 14, 2025

      Dr. Resneck is great. Always spends plenty of time in answering questions and listening to any concerns

    • 5 out of 5 Stars
      November 4, 2025

      Always so thorough, comprehensive, and engaging.

    • 5 out of 5 Stars
      October 21, 2025

      Dr. Resneck is a jewel. Great Dr and human being.

    • 5 out of 5 Stars
      October 2, 2025

      The doctor was terrific. I really appreciated his expertise and help throughout the visit.

    • 5 out of 5 Stars
      September 30, 2025

      Dr. Resneck is an excellent clinician and really cares about his work and patients

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.